Synchron Secures $200 Million to Boost Brain-Computer Interface for Paralysis
Synchron announced the successful closing of a $200 million Series D funding round aimed at expanding its operations and speeding up the commercialization of its non-surgical brain-computer interface (BCI) technology designed to aid people with paralysis.
Funding Details and Investors
The round was led by Double Point Ventures and included participation from existing investors such as Arch Ventures, Khosta Ventures, Bezos Expeditions, NTI, and Metis. Additional investors joining the round were the Australian National Reconstruction Fund, T.Rx Capital, the Qatar Investment Authority, K5 Global, Protocol Labs, and IQT.
Company Growth and Industry Momentum
With this latest funding, New York-based Synchron has raised a total of $345 million. The infusion of capital reflects increasing momentum in the brain-computer interface sector, particularly for companies developing solutions to support individuals with paralysis.
Recent Developments in Brain-Computer Interfaces
- Precision Neuroscience recently announced a partnership with SCI Ventures, a fund supported by the Christopher & Dana Reeve Foundation, to advance its Layer 7 Cortical Interface.
- A study published last month highlighted Science Corp.’s PRIMA retinal implant, which helped restore some vision for patients with advanced age-related macular degeneration.
"Synchron has reeled in another $200 million in a series D round—cash the company said it will use to expand operations and accelerate commercialization of its non-surgical brain-computer interface for people with paralysis."
Author's summary: Synchron's substantial funding round marks a pivotal step in bringing non-invasive brain-computer interface technology closer to widespread clinical use for paralysis treatment.